Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04362072
Other study ID # B7461027
Secondary ID 2019-002504-41
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date September 29, 2020
Est. completion date June 25, 2024

Study information

Verified date March 2024
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to learn whether the study medicine (called lorlatinib) is safe and effective for the treatment of non-small cell lung cancer that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene. This study is seeking participants whose lung cancer has progressed after receiving either alectinib or ceritinib as their first treatment. Participants will take part in this study for up to approximately 4 years, depending on when the study is completed and how their cancer responds to the study treatment. They will take lorlatinib orally (by mouth) once daily. Participants will visit the study site about every six weeks to meet with the study team. During these visits, the study team will monitor the safety and effects of lorlatinib.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 71
Est. completion date June 25, 2024
Est. primary completion date June 25, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must have evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC (Stage IV, American Joint Committee on Cancer [AJCC] v7.0) that carries an ALK rearrangement. - Disease Status Requirements: disease progression after alectinib or ceritinib as first line therapy (the study will limit enrollment of participants with best response of progression or indeterminate on prior alectinib to 8 participants). Participants may have had prior chemotherapy, but only if before starting treatment with alectinib or ceritinib. - Tumor Requirements: All Participants must have at least one measurable target extracranial lesion according to RECIST v1.1. Participants with asymptomatic CNS metastases (including participants controlled with stable or decreasing steroid use within the last 2 weeks prior to study entry) will be eligible. Participants who have leptomeningeal disease (LM) or carcinomatous meningitis (CM) will be eligible if the LM/CM is visualized on magnetic resonance imaging (MRI) or if documented baseline cerebral spinal fluid (CSF) positive cytology is available. - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. - Adequate bone marrow functioning, pancreatic function, renal function and liver function - Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade =1 except for adverse events (AEs) that in the investigator' judgment do not constitute a safety risk for the participant. - Systemic anti-cancer therapy with alectinib or ceritinib discontinued within a minimum of 5 half-lives prior to first dose of lorlatinib on the study (unless clinically meaningful tumor flare per discretion of the investigator, in which discussion with the sponsor is warranted). - Male participants are eligible to participate if they agree to use proper contraception during the intervention period and for at least 98 days after the last dose of study intervention - Female participants are eligible to participate if they are not pregnant or breastfeeding, and agree to use proper contraception during the intervention period and for at least 35 days after the last dose of study intervention. - Capable of giving signed informed consent and willingness and ability to comply with the study scheduled visits and other procedures. Exclusion criteria: - Prior ALK TKI treatment or anti-cancer treatment other than first line alectinib or ceritinib. - Spinal cord compression unless the participant has good pain control attained through therapy, and there is stabilization or recovery of neurological function for the 4 weeks prior to randomization. - Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes. - Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness. - Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions, (active or within 3 months prior to enrollment) - Participants presenting with abnormal Left Ventricular Ejection Fraction (LVEF) by echocardiogram or Multi-Gated Acquisition Scan according to institutional lower limits. - Participants with predisposing characteristics for acute pancreatitis according to investigator judgment - History or known presence of interstitial fibrosis, interstitial lung disease, pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis. - Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study. - Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ (DCIS) of the breast or localized and presumed cured prostate cancer) within the last 3 years prior to randomization. - Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation must have been completed at least 48 hours prior to study entry. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry. - Prior irradiation to >25% of the bone marrow. - Concurrent use of any of the following food or drugs within 12 days prior to the first dose of lorlatinib: known strong CYP3A inducers, known strong CYP3A inhibitors, known CYP3A substrates with narrow therapeutic index, known permeability glycoprotein (P-gp) substrates with a narrow therapeutic index - Major surgery within 4 weeks prior to enrollment. - Known prior or suspected severe hypersensitivity to study interventions or any component in their formulations. - Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.

Study Design


Intervention

Drug:
Lorlatinib
25 milligram (mg) tablet

Locations

Country Name City State
India Healthcare Global Enterprises Bengaluru Karnataka
India Medanta-The Medicity Gurgaon Haryana
India Rajiv Gandhi Cancer Institute And Research Centre New Delhi Delhi
India Rajiv Gandhi Cancer Institute And Research Centre New Delhi DEL
India Bhakti Vedanta Hospital and Research Institute Thane Maharashtra
Italy Azienda Ospedaliera San Giuseppe Moscati Avellino
Italy Centro Riferimento Oncologico di Aviano - IRCCS SOC Oncologia Medica e dei Tumori Immunocorrelati Aviano PN
Italy Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia Candiolo Torino
Italy Policlinico "G. Rodolico" Catania
Italy IRCCS Ospedale San Raffaele Milano MI
Italy Fondazione IRCCS San Gerardo dei Tintori Monza Lombardia
Italy Ospedale San Gerardo ASST Monza Oncologia Medica Monza Monza AND Brianza
Italy Azienda Ospedaliera Dei Colli Naples Napoli
Italy AOU San Luigi Gonzaga Orbassano (TO) TO
Italy Azienda Ospedaliero Universitaria di Parma Parma PR
Italy AO Santa Maria della Misericordia Perugia Umbria
Italy A.O. Ospedali Riuniti Marche Nord - Presidio San Salvatore - Muraglia Pesaro PU
Italy Azienda Sanitaria Territoriale (AST) Pesaro Urbino Pesaro Pesaro AND Urbino
Italy Azienda Ospedaliera San Camillo Forlanini Roma Rome
Poland Centrum Medyczne Luxmed Sp. z o.o. Lublin
Poland Elkardia Lubelskie Centrum Kardiologii Lublin
Poland Ms Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Spolka Jawna Lublin
Poland Centrum Medyczne EVOMED Szczecin
Poland Dom Lekarski Centrum Medyczne Outlet Park Szczecin
Poland Dom Lekarski S.A. Szczecin
Poland Pracownia Medycyny Nuklearnej, 109 Szpital Wojskowy z Przychodnia SP ZOZ Szczecin
Poland Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Tadeusza Sokolowskiego Pomorskiego UM Szczecin
Spain Hospital Teresa Herrera (C.H.U.A.C) A Coruña
Spain Hospital de la Santa Creu i Sant Pau Barcelona
Spain Hospital de la Santa Creu i Sant Pau Barcelona
Spain Hospital Universitari Vall d'Hebron Barcelona
Spain ICO L'Hospitalet (Hospital Duran i Reynals) L'Hospitalet de Llobregat
Spain Hospital Universitario Ramon y Cajal Madrid
Spain Hospital Universitario Puerta de Hierro Majadahonda Majadahonda Madrid
Spain Hospital Regional Universitario de Malaga Malaga
Spain Hospital Universitario Virgen del Rocio Sevilla
Spain Hospital Universitari i Politecnic La Fe Valencia
Switzerland Kantonsspital Graubuenden Chur Graubuenden
United Kingdom Guy's and St Thomas' NHS Foundation Trust London
United Kingdom NIHR/Wellcome Trust Clinical Research Facility Manchester
United Kingdom The Christie NHS Foundation Trust Manchester
United States University Cancer & Blood Center, Llc Athens Georgia
United States UCI Medical Center/Chao Family Comprehensive Cancer Center Orange California

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  India,  Italy,  Poland,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Patients With Overall Objective Response (OR) based on independent central review (ICR) OR (Objective Response) based on ICR assessment is defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. every 6 weeks up to approximately 4 years
Secondary Percentage of Patients With Overall OR based on Investigator (INV) OR based on INV assessment is defined as CR or PR according to RECIST v1.1. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. every 6 weeks up to approximately 4 years
Secondary Percentage of Patients With Intra-Cranial Objective Response (IC-OR) based on ICR/derived INV IC-OR is defined as Intra-Cranial complete response (IC-CR) or partial response (IC-PR) according to RECIST v1.1. Both IC-CR and IC-PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. every 6 weeks up to approximately 4 years
Secondary Time to Response (TTR) based on ICR/derived INV TTR is defined, for participants with a confirmed OR, as the time from the date of first dose to the first documentation of objective response (CR or PR) which is subsequently confirmed. every 6 weeks up to approximately 4 years
Secondary Time to Intra-Cranial Response (IC-TTR) based on ICR/derived investigator IC-TTR is defined, for participants with a confirmed intra-cranial objective response, as the time from the date of first dose to the first documentation of objective intra-cranial response (CR or PR) which is subsequently confirmed. every 6 weeks up to approximately 4 years
Secondary Duration of Response (DoR) based on ICR/ derived investigator DoR is defined, for participants with a confirmed objective response, as the time from first documentation of objective response (CR or PR whichever is earlier) to the date of first documentation of PD or death due to any cause, whichever occurs first every 6 weeks up to approximately 4 years
Secondary Duration of Intra-Cranial Response (IC-DoR) based on ICR/ derived INV IC-DoR is defined, for participants with a confirmed objective intra-cranial response, as the time from first documentation of objective intra-cranial response (CR or PR whichever is earlier) to the date of first documentation of PD in brain or death due to any cause, whichever occurs first. every 6 weeks up to approximately 4 years
Secondary Progression Free Survival (PFS) based on ICR/derived INV PFS is defined as the time from date of first dose to the date of the first documentation of PD (per RECIST v1.1) or death due to any cause, whichever occurs first. every 6 weeks up to approximately 4 years
Secondary Time To Progression (TTP) based on ICR/derived INV TTP is defined as the time from date of first dose to the date of the first documentation of PD (per RECIST v1.1). every 6 weeks up to approximately 4 years
Secondary Adverse Event (AE) as graded by NCI CTCAE (v 4.03) Frequency of patients experiencing treatment-emergent AEs (TEAEs) From study start up to approximately 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT05283226 - Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy Phase 2
Completed NCT04033991 - Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Recruiting NCT02292641 - Beyond TME Origins N/A
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT01942200 - A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
Completed NCT01061645 - Study of MOC31-PE in Antigen Positive Carcinomas Phase 1
Terminated NCT00557596 - A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT00532155 - A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Phase 3
Completed NCT00216372 - Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis Phase 3
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Recruiting NCT05752357 - The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.
Not yet recruiting NCT05023928 - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer Phase 1
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Not yet recruiting NCT06112041 - The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) Phase 2
Completed NCT03562897 - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer Phase 2
Recruiting NCT06013111 - An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT04600206 - Existential Distress in Patients With Advanced Cancer and Their Caregivers